Interpace Biosciences's latest marketcap:
As of 06/08/2025, Interpace Biosciences's market capitalization has reached $3.45 M. According to our data, Interpace Biosciences is the 44500th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.45 M |
| Revenue (ttm) | 48.26 M |
| Net Income (ttm) | 7.18 M |
| Shares Out | 4.42 M |
| EPS (ttm) | 0.33 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/11/2025 |
Interpace Biosciences's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/08/2025 | $3.45 M | -70.94% |
| 12/31/2024 | $11.87 M | 152.98% |
| 12/29/2023 | $4.69 M | 5.76% |
| 12/30/2022 | $4.44 M | -85.77% |
| 12/31/2021 | $31.18 M | 145.72% |
| 12/31/2020 | $12.69 M |
Company Profile
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. is a molecular diagnostics company specializing in cancer risk assessment through advanced testing, bioinformatics, and pathology services. Headquartered in Parsippany, New Jersey, the company serves healthcare providers across the United States.
Key Products & Services
- PancraGEN® – A genomic test for pancreatic cysts and solid lesions, utilizing the proprietary PathFinderTG® platform.
- PanDNA® – A molecular-only variant of PancraGEN® for pancreaticobiliary cancer diagnosis.
- ThyGeNEXT® – An oncogenic mutation panel designed to identify malignant thyroid nodules.
- ThyraMIR® v2 – A microRNA-based gene expression classifier to assess thyroid nodule malignancy risk.
- RespriDx™ – A genomic test aiding in the differentiation of metastatic or recurrent lung cancer.
Customer Base
Interpace Biosciences primarily serves:
- Physicians
- Cancer centers & clinics
- Laboratories & pathology groups
- Hospitals
Company Background
Originally incorporated in 1986 as Interpace Diagnostics Group, Inc., the company rebranded as Interpace Biosciences, Inc. in November 2019. With decades of expertise, it remains a leader in precision diagnostics for oncology.
Frequently Asked Questions
-
What is Interpace Biosciences's (OTC-IDXG) current market cap?As of 06/08/2025, Interpace Biosciences (including the parent company, if applicable) has an estimated market capitalization of $3.45 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Interpace Biosciences (OTC-IDXG) rank globally by market cap?Interpace Biosciences global market capitalization ranking is approximately 44500 as of 06/08/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.